Jozefow

• A study to investigate the pharmacokinetics and safety of KM04 compared to US-Gonal-f RFF Redi-ject and EU-Gonal-f in healthy adult female v … Not authorised
  2025-523368-19-00 2 Functional female infertility
• A study to compare the relative potency of salbutamol administered via metered dose inhalers containing propellants HFA-152a to HFA-134a in … Pending
  2024-511220-14-00 3 Mild Asthma
• A First-in-Human, Open-label, Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy o … Pending
  2025-525113-22-00 1 Rheumatoid Arthritis
• A Phase 1b, Open-Label Study of CLN-978 for the Treatment of Active, Moderate to Severe Sjogren’s Disease Recruiting
  2025-521462-96-00 3 2025-08-05 Sjogren's Disease
• A Phase I, Open-Label Study of CLN-978 in Patients with Treatment-Refractory Rheumatoid Arthritis (RA) Recruiting
  2024-519114-31-00 3 2025-05-15 Treatment-Refractory Rheumatoid Arthritis
• A phase 1 multi-centre, randomized, single-blind, steady-state study to evaluate pharmacokinetics, pharmacodynamics, safety and tolerability … Recruiting
  2024-516197-30-00 3 2025-07-16 Idiopathic or diabetic gastroparesis
• A Phase I/II study of GSK5733584 in combination with anti-cancer therapies for advanced solid tumors Recruiting
  2024-517147-31-00 9 2025-05-23 Tumours, Gynecological
• A First-in-Human Study to Evaluate the Safety and Anti-cancer Activity of the product FS222, which is an Antibody medication, in Subjects wi … Recruiting
  2024-514010-12-00 1 2020-12-03 Advanced Malignancies
• A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants with Severe Hypertriglyceridemia (SHTG) Ended recruitment
  2022-501999-26-00 5 2023-07-12 Severe Hypertriglyceridemia (SHTG)
• A Phase 1 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Tarlatamab in Subjects With Small Cell Lung Cancer (DeLLphi-300 … Ended recruitment
  2023-506541-39-00 1 2018-08-03 Small Cell Lung Cancer
• Comparison of Prefilled syringe and Autoinjector presentations of FYB202 Ended
  2025-522422-13-00 2 2025-11-15 Chronic inflammatory diseases
• A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia Ended
  2022-501420-20-00 5 2023-05-17 Severe hypertryglyceridemia
• A Phase 1 open-label, first-in-human, multi-center, dose escalation and dose expansion study of CLN-619 administered alone or in combination … Ended
  2024-511744-27-00 1 2022-06-27 Solid tumors, Non-Small Cell Lung Cancer, Cervical Cancer, Endometrial
• Study Comparing Bemarituzumab plus Chemotherapy with Placebo and Chemotherapy in Previously Untreated Advanced Gastric or Gastroesophageal J … Ended
  2023-505457-40-00 5 2022-02-02 Previously Untreated Advanced Gastric or Gastroesophageal Junction Can
• Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended
  2023-503673-38-00 5 2019-05-24 Adults at high risk of cardiovascular events without prior MI or strok

Showing 1–15 of 15 trials